Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
The European stock markets closed mostly lower in Tuesday trading as The Stoxx Europe 600 was down 0.55%, France's CAC fell 0.72%, the FTSE in London lost 1.36%, Germany's DAX dropped 0.20%, while the ...